C(=O)N1C/C(=C\C2=CC(Cl)=C(Cl)C=C2)/C(=O)/C(/C1)=C/C1=CC(Cl)=C(Cl)C=C1](https://cdn.shopify.com/s/files/1/0389/1897/9723/products/M8719_1621504072.gif?v=1629706157)
Pay in 4 interest-free payments of $26.25 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Smiles: N[C@@H](CC1C=CC=CC=1)C(=O)N1C/C(=C\C2=CC(Cl)=C(Cl)C=C2)/C(=O)/C(/C1)=C/C1=CC(Cl)=C(Cl)C=C1
8-dihydroxy-2H-1-benzopyran-2-one
is a selective inhibitor of transforming growth factor-β type I receptor (ALK5
Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone
Ruxolitinib (S) 05 trifluoroacetate Smiles: N[C@@H](CC1C=CC=CC=1)C(=O)N1C/C(=C\C2=CC(Cl)=C(Cl)C=C2)/C(=O)/C(/C1)=C/C1=CC(Cl)=C(Cl)C=C1S Ruxolitinib is a less active enantiomer of Ruxolitinib, a JAK1 2 inhibitor. S Ruxolitinib was initially developed to target the constitutive activation of the JAK STAT pathway. Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. Ruxolitinib maintains its anti JAK activity by competitive
US$ 370.50
US$ 205.50
US$ 107.00